An antithrombin III result on a lab report is one of the few numbers that describes how well your blood knows when to stop clotting. Antithrombin III is a protein made by your liver that acts as a natural brake on coagulation, and when the test comes back low, it usually means that brake is weaker than it should be. In this article you will learn what the test actually measures, how to read the percentage on your report, why activity and antigen results can disagree, what pushes the number down temporarily, and which situations make the result clinically meaningful rather than just unusual. The goal is not to diagnose anything, but to help you walk into your next appointment knowing which questions matter.
What antithrombin III is and what it does in your blood
Clotting is a controlled emergency. When a vessel is injured, a cascade of proteins activates in sequence until fibrin strands seal the leak. That cascade needs an off switch, otherwise a small repair would keep growing until it blocked the vessel entirely. Antithrombin is that off switch. It circulates continuously and neutralizes thrombin and factor Xa, the two enzymes that drive the final steps of clot formation.
The name is a historical leftover. Researchers once numbered several antithrombin activities, and the third one turned out to be the important circulating inhibitor. Modern laboratories and modern literature simply call it antithrombin, but American lab reports still print the older label, so you may see both terms for the same protein on the same page.
Antithrombin works slowly on its own. Heparin, whether the natural heparan sulfate lining your vessel walls or the drug given in a hospital, binds to antithrombin and changes its shape, accelerating its braking action by a factor of hundreds. That relationship explains a clinical detail many patients find confusing: heparin does not thin blood by itself. It works by amplifying the antithrombin you already have, which is why someone with very little antithrombin can respond poorly to standard heparin doses.
Because antithrombin is only one of several natural anticoagulants, doctors rarely read it alone. It sits alongside two related inhibitor proteins, and if you want the full picture you can compare it with our coagulation panel results guide.
Why a doctor orders an antithrombin III test
This is not a routine screening test. It is not part of a standard annual physical, and it does not appear on a basic metabolic panel or a complete blood count. It is ordered when a specific question needs answering.
Common reasons for testing
- An unexplained blood clot in a deep vein or in the lungs, particularly in someone under about 50 with no obvious trigger such as surgery or a long period of immobility.
- Clots that keep coming back despite treatment, or clots in unusual locations such as the veins of the abdomen or the brain.
- A strong family history of clotting, especially when a close relative has a confirmed antithrombin deficiency.
- Heparin that is not producing the expected anticoagulant effect at normal doses, a pattern sometimes described as heparin resistance.
- Repeated pregnancy loss or a clotting event during pregnancy or in the weeks after delivery.
Doctors often order antithrombin together with other clotting studies rather than in isolation. A workup may include a D-dimer test guide to gauge whether clot breakdown is currently active, along with screening times that measure the cascade itself. Two of those screens are explained in our prothrombin time results guide and our partial thromboplastin time explainer.
One point deserves emphasis. Finding a low antithrombin level does not by itself mean you will develop a clot, and a normal level does not guarantee you will not. Most people carrying an inherited clotting tendency never experience a thrombosis. The result adjusts a probability; it does not settle a fate.
How to read your antithrombin III test results
Antithrombin activity is reported as a percentage of what a pooled normal plasma sample would do, so 100% means average, not perfect. Many United States laboratories use an adult reference interval close to 80% to 120%, but intervals differ between analyzers and reagent lots. The range printed beside your own value is the only one that applies to your sample.
The table below shows how clinicians generally think about the bands. Treat it as an orientation aid for a conversation with your doctor, not as a self-assessment tool.
| Activity result | Usual interpretation | Typical next step |
|---|---|---|
| Within the printed reference interval | Natural braking capacity appears adequate | No antithrombin follow-up unless symptoms suggest otherwise |
| Mildly below the interval | Often a temporary or acquired dip rather than an inherited defect | Repeat once the acute situation has resolved |
| Roughly half of normal, confirmed on a second sample | Pattern most often seen in inherited deficiency | Antigen testing, family assessment, hematology referral |
| Very low during a clot, sepsis, or heparin therapy | Consumption by the illness itself is the usual explanation | Defer classification until recovery |
| Above the interval | Rarely significant on its own | Usually no action; interpreted with the rest of the panel |
Timing matters more here than with most blood tests. A sample drawn during an active clot, while on heparin, or in the middle of a serious infection can read low for reasons that have nothing to do with your genes. That is why hematologists prefer to confirm a low value weeks later, once the acute episode has passed and anticoagulant treatment has been adjusted or stopped under supervision.
Activity and antigen: why one protein produces two numbers
Laboratories can measure antithrombin two different ways, and the pair of results tells a story that neither number tells alone.
The functional assay, usually the first one run, measures how well your antithrombin actually inhibits thrombin or factor Xa. The immunologic assay, called the antigen test, measures how much antithrombin protein is physically present, whether or not it works. Comparing them separates two very different problems.
| Pattern | Activity | Antigen | What it suggests |
|---|---|---|---|
| Type I deficiency | Low | Low | Too little protein is being made; quantity is the problem |
| Type II deficiency | Low | Normal | Enough protein is present but it does not work properly |
| Acquired dip | Low | Low | Loss or consumption from illness, not from an inherited variant |
| Normal study | Normal | Normal | No antithrombin abnormality detected on this sample |
Inherited antithrombin deficiency traces back to the SERPINC1 gene, which carries the instructions for building the protein. It is inherited in an autosomal dominant pattern, meaning a single altered copy is enough to lower the level, and each child of an affected parent has an even chance of inheriting it. Type II is further divided according to which part of the molecule is affected, and some type II subtypes carry noticeably less clot risk than others, which is one reason a hematologist rather than a general reference table should classify the result.
The functional assay is the one that catches both types, so it is always the starting point. A patient-level walkthrough of that assay is available in our antithrombin activity lab test guide.
What lowers antithrombin III, and what raises it
Acquired causes are far more common than inherited ones, and most of them are temporary.
Causes of a low result
- Liver disease. The liver manufactures antithrombin, so significant liver impairment reduces output. Production markers often fall together, which is why doctors read the result beside our albumin test results guide.
- Kidney disease with heavy protein loss in the urine, since antithrombin is small enough to escape through damaged filters.
- An active clot, major surgery, trauma, or sepsis, all of which consume inhibitor proteins quickly.
- Heparin treatment, which lowers measured levels modestly during therapy.
- Estrogen exposure, including combined oral contraceptives and hormone therapy.
- Pregnancy and the postpartum weeks, when the whole clotting system shifts toward a more clot-prone state.
Causes of a higher result
High antithrombin is rarely a clinical concern. It appears with vitamin K antagonist therapy such as warfarin, during some inflammatory states, and occasionally with kidney transplantation. There is no established condition of dangerous antithrombin excess, so an elevated value is usually noted and set aside.
Because these acquired causes overlap so heavily with the reasons a clotting workup gets ordered in the first place, the sequence of testing matters. A level measured in a hospital bed during an acute event answers a different question than one measured three months later in a clinic. Fibrinogen behaves similarly under stress, as our fibrinogen blood level guide explains.
Special situations: pregnancy, heparin, and surgery
Three contexts change how the number is used.
Pregnancy
Pregnancy already raises clot risk substantially compared with the non-pregnant state, and antithrombin deficiency raises it further. Obstetric teams therefore treat a known deficiency as a planning matter rather than a monitoring matter, deciding in advance about preventive anticoagulation during pregnancy and after delivery. Testing during pregnancy itself is discouraged because the physiological shift makes results hard to classify.
Heparin resistance
When standard heparin doses fail to produce the expected effect, low antithrombin is one of the explanations clinicians check, particularly in intensive care and during cardiac surgery with bypass. Because heparin needs antithrombin as a partner, replacing antithrombin can restore the drug’s effect in selected cases. Monitoring in that setting relies on clotting times rather than the antithrombin level itself, and our INR meaning explainer covers the most familiar of those measurements.
Surgery and immobility
Someone with a confirmed deficiency is usually offered clot prevention around operations, long hospital stays, and prolonged travel, even without a prior clot. The condition being managed is risk, not illness. Recognizing the symptoms that warrant urgent care remains essential, and those are set out in our deep vein thrombosis symptoms guide.
What to do after an abnormal antithrombin III result
A single low value is a starting point, not a conclusion. The following sequence reflects how specialists typically proceed.
- Check the context of the draw. Were you on heparin, recovering from a clot, pregnant, acutely ill, or taking estrogen? If so, the result may not represent your baseline.
- Repeat the test after the situation resolves, generally several weeks later and off interfering treatment when that is safe to arrange.
- Add antigen testing if activity is still low, to separate a quantity problem from a quality problem.
- Review family history, since an inherited deficiency has implications for siblings, parents, and children.
- Discuss prevention rather than treatment if no clot has occurred. Most people with a deficiency and no clotting history are not placed on lifelong anticoagulation.
When to seek medical attention promptly
Regardless of any lab value, seek urgent care for swelling, pain, warmth, or discoloration in one leg, or for sudden shortness of breath, chest discomfort that worsens with a deep breath, coughing up blood, or a racing heartbeat. Roughly half of deep vein clots produce no symptoms at all, which is why known risk factors deserve a plan rather than watchful waiting. Platelet behavior is part of the same broader picture, as our platelet count results guide describes.
Latest scientific advances
Research published over the past three years has shifted the conversation about antithrombin testing away from who can be tested and toward who should be. Here is what recent reviews found, in plain terms.
Testing selectively beats testing everyone
A 2025 review in Medical Clinics of North America examined how thrombophilia testing, meaning the search for inherited clotting tendencies, is actually used after a venous clot. The authors found wide variation between medical centers in who gets tested and how the results are applied, and concluded that indications should be narrow and deliberate. What this means for you: if your doctor declines to order a clotting panel after a clot with a clear cause such as surgery, that is current practice rather than an oversight.
A positive result does not automatically change treatment
A 2024 review in Presse Médicale looked at how much thrombophilia findings actually alter management. For the more common inherited variants, the answer was surprisingly little, because the decision about how long to continue anticoagulation is driven mainly by whether the clot had an identifiable trigger. Antithrombin deficiency sits at the more consequential end of that spectrum, but even there the finding informs a discussion rather than dictating a protocol. What this means for you: expect your treatment plan to be built around your clot history first and your lab result second.
Laboratory pitfalls are being catalogued
A 2024 review in Seminars in Thrombosis and Hemostasis detailed how easily thrombophilia results can mislead. Anticoagulant drugs, the timing of the draw relative to a clot, and assay design can all push a value in the wrong direction, and some assay formats miss particular subtypes of antithrombin defect. What this means for you: a single abnormal number should be confirmed before it becomes a label, and confirmation is a normal part of good practice rather than a sign that something went wrong.
Clearer guidance for clinicians who order the test
A 2026 review in the Journal of the American Association of Nurse Practitioners summarized the five classic inherited thrombophilias, antithrombin deficiency among them, and reinforced that most people who carry one never develop a clot. It also stressed that testing should follow a defined clinical question and be paired with counseling. What this means for you: if you are offered this test, it is reasonable to ask what decision the result will change, and a good clinician will have a concrete answer.
None of this research overturns the basics. Antithrombin remains a meaningful marker of your natural clot-braking capacity. The refinement is about context, timing, and restraint rather than about the biology.
Glossary of key terms
| Term | Definition |
|---|---|
| Antithrombin (antithrombin III) | A liver-made protein that slows clotting by neutralizing thrombin and factor Xa. The Roman numeral is a historical label for the same protein. |
| Thrombin | The enzyme that converts fibrinogen into fibrin, the mesh that holds a clot together. |
| Thrombophilia | A tendency toward abnormal clotting, either inherited or acquired later in life. |
| Venous thromboembolism (VTE) | An umbrella term covering deep vein thrombosis and pulmonary embolism, a clot that has traveled to the lungs. |
| Functional assay | A test that measures how well a protein works rather than how much of it is present. |
| Antigen assay | A test that measures the physical amount of a protein, regardless of whether it functions normally. |
| SERPINC1 | The gene carrying the instructions for building antithrombin. Variants in it cause hereditary antithrombin deficiency. |
| Autosomal dominant | An inheritance pattern in which one altered gene copy is enough to produce the trait, giving each child a one-in-two chance of inheriting it. |
| Heparin resistance | A situation in which usual heparin doses produce less anticoagulant effect than expected, sometimes because antithrombin is low. |
| Reference interval | The range of values a laboratory considers typical for its own method, printed beside your result. |
Frequently asked questions
Do I need to fast before an antithrombin III test?
Fasting is not usually required for this test. It is a standard venous blood draw that takes a few minutes. What does matter is your medication list and your recent medical history, because heparin, warfarin, direct oral anticoagulants, estrogen-containing medications, and a recent clot can all shift the result. Tell the ordering clinician exactly what you take and when your last dose was, and mention any recent hospitalization, surgery, infection, or pregnancy. If the test is being done as part of a workup after a clot, the laboratory or your doctor may schedule it for a specific time relative to your treatment rather than drawing it the same day.
Can a low antithrombin III level return to normal?
Yes, when the cause is acquired. Levels that dropped because of an active clot, surgery, sepsis, heparin therapy, or a temporary liver problem often recover once the underlying situation resolves. That is precisely why a single low value is generally repeated after several weeks. An inherited deficiency caused by a SERPINC1 variant, by contrast, is lifelong and will not normalize, although the level can still fluctuate somewhat around its own baseline. Only repeat testing under stable conditions, ideally paired with an antigen measurement, can distinguish the two situations reliably.
Does antithrombin deficiency mean I will definitely get a blood clot?
No. Carrying an inherited clotting tendency raises the probability of a clot over a lifetime, but most people who carry one never experience a thrombosis. Antithrombin deficiency is considered one of the stronger inherited risk factors, so it warrants more attention than some others, yet it still interacts with circumstances such as surgery, immobility, pregnancy, and hormone use. The practical consequence is usually a prevention plan for high-risk periods rather than continuous treatment. Your personal and family clotting history weighs at least as heavily as the number itself.
Should my family members be tested?
It depends on the finding and on their own history, so this is a conversation to have with a hematologist or genetic counselor rather than a decision to make from a lab report. Because the deficiency follows an autosomal dominant pattern, first-degree relatives have roughly a one-in-two chance of carrying the same variant. Testing may be offered to relatives who are pregnant, planning pregnancy, considering estrogen-containing contraception, or facing major surgery, because the result could change preventive care. Testing children without a clear clinical reason is generally deferred.
Can I still take birth control pills with a low antithrombin III level?
That decision belongs to your clinician, who will weigh your result, your clotting history, your family history, and the alternatives available. Combined estrogen-containing contraceptives increase clot risk in the general population, and that increase is amplified when a clotting tendency is present. Progestin-only methods and non-hormonal options are frequently discussed in this situation. Do not stop a prescribed medication on the basis of a lab value alone; bring the result to the appointment and ask specifically how it affects your options.
How is antithrombin III different from protein C and protein S?
All three are natural anticoagulants, meaning proteins that restrain clotting, but they work through different mechanisms and are measured by different assays. Antithrombin directly neutralizes thrombin and factor Xa. Protein C and protein S work as a pair to inactivate other clotting factors further upstream in the cascade. A thrombophilia workup often measures all three together, along with genetic tests for two common variants, because a deficiency in any one of them can contribute to clot risk.
Sources
- Vrotniakaite-Bajerciene K, Angelillo-Scherrer A, Castellucci LA — Thrombophilia Testing in Venous Thromboembolism — Medical Clinics of North America, 2025 — doi.org/10.1016/j.mcna.2025.01.008
- Emmerich J, Zuily S, Gouin-Thibault I, Morange PE, Couturaud F, Huisman M — Impact of thrombophilia on venous thromboembolism management — La Presse Médicale, 2024 — doi.org/10.1016/j.lpm.2024.104247
- Moore GW — Thrombophilia Screening: Not So Straightforward — Seminars in Thrombosis and Hemostasis, 2024 — doi.org/10.1055/s-0044-1786807
- Tinkle MB — Inherited thrombophilias: Genetics and testing considerations — Journal of the American Association of Nurse Practitioners, 2026 — doi.org/10.1097/JXX.0000000000001216
- MedlinePlus Genetics, National Library of Medicine — SERPINC1 gene — MedlinePlus Genetics, reviewed 2024 — medlineplus.gov
- National Heart, Lung, and Blood Institute — Venous Thromboembolism — National Institutes of Health, 2025 — nhlbi.nih.gov
- Centers for Disease Control and Prevention — About Venous Thromboembolism (Blood Clots) — CDC, updated 2025 — cdc.gov
- Mayo Clinic — Deep vein thrombosis (DVT): Symptoms and causes — Mayo Foundation for Medical Education and Research, 2022 — mayoclinic.org
Further reading
- Compare the other natural anticoagulant measured alongside antithrombin by reading our protein C blood test guide.
- Examine the cofactor that partners with protein C in our protein S test results guide.
- Review the panel that frames almost every blood workup with our complete blood count results guide.
- Explore a separate amino acid linked to vascular risk in our homocysteine blood level guide.
- Understand what platelet size adds to a clotting assessment with our mean platelet volume results guide.
Understand your lab results with BloodSense
Get your results interpreted in minutes
Clotting results rarely make sense in isolation. An antithrombin percentage means something different depending on what your prothrombin time, partial thromboplastin time, D-dimer, and platelet count are doing at the same moment. BloodSense reads those numbers together and explains in plain language what each one contributes, so you arrive at your appointment with informed questions instead of a page of unfamiliar abbreviations. It helps you understand your report; it does not diagnose you and it does not replace your doctor.
